论文部分内容阅读
目的:探析乙型肝炎加急性肝衰竭病症在解毒凉血治疗下的临床疗效。方法:将2014年12月—2015年12月于医院接受治疗的90例乙型肝炎加急性肝衰竭患者选为分析的对象,并随机将其分均为对照组与观察组,对照组予以西药治疗,观察组在对照组的基础上予以解毒凉血法治疗,比较两组患者的临床疗效、肝功能(凝血酶原活动度(PTA)、总胆红素(TBIL)、血清白蛋白(ALB))情况、并发症的发生情况等。结果:观察组的治疗总有效率(97.78%)高于对照组(75.56%),肝功能指标:PTA(74.25±10.20)%、TBIL(121.85±30.10)μmol/L、ALB(45.56±6.23)g/L指标均较对照组的PTA(50.45±10.25)%、TBIL(242.65±30.15)μmol/L、ALB(32.78±6.10)g/L指标趋于正常值,且并发症的发生率(6.67%)低于对照组(35.56%),比较的结果均具有统计学意义(P<0.05)。结论:乙型肝炎加急性肝衰竭病症在解毒凉血治疗下的疗效尤为显著,不仅可以有效地改善患者的肝功能,而且降低并发症的发生率,值得临床广泛应用。
Objective: To investigate the clinical efficacy of hepatitis B plus acute liver failure in the treatment of detoxification and cooling blood. Methods: Ninety patients with hepatitis B plus acute hepatic failure who were treated in the hospital from December 2014 to December 2015 were selected as the subjects for analysis, and randomly divided into the control group and the observation group, while the control group received the western medicine The observation group was treated with detoxification and cooling blood on the basis of the control group. The clinical effects, liver function (PTA, total bilirubin (TBIL), serum albumin (ALB) )), The incidence of complications and so on. Results: The total effective rate (97.78%) in the observation group was significantly higher than that in the control group (75.56%). The liver function indexes were PTA (74.25 ± 10.20)%, TBIL (121.85 ± 30.10) μmol / L and ALB (45.56 ± 6.23) g / L were higher than those of the control group (PTA 50.45 ± 10.25%, TBIL 242.65 ± 30.15 μmol / L, ALB 32.78 ± 6.10 g / L), and the incidence of complications was 6.67 %) Was lower than the control group (35.56%), the results of the comparison were statistically significant (P <0.05). Conclusion: Hepatitis B plus acute liver failure is particularly effective in treating patients with detoxification and cooling blood. It can not only effectively improve the liver function of patients but also reduce the incidence of complications, which deserves wide application in clinic.